Biocompatible and Antibacterial Nitric Oxide-Releasing Pluronic F-127/Chitosan Hydrogel for Topical Applications

被引:71
作者
Pelegrino, Milena T. [1 ,2 ]
Lima, Bruna de Araujo [3 ]
do Nascimento, Monica H. M. [2 ,3 ]
Lombello, Christiane B. [1 ,4 ]
Brocchi, Marcelo [3 ]
Seabra, Amedea B. [1 ,2 ]
机构
[1] Univ Fed ABC, Ctr Nat & Human Sci, Av Estados 5001, BR-09210580 Santo Andre, SP, Brazil
[2] Univ Fed ABC, Nanomed Res Unit NANOMED, Av Estados 5001, BR-09210580 Santo Andre, SP, Brazil
[3] Univ Estadual Campinas, Inst Biol, Trop Dis Lab, Dept Genet Evolut Microbiol & Immunol, BR-13083862 Campinas, SP, Brazil
[4] Univ Fed ABC, Ctr Engn Modeling & Appl Social Sci, Alameda Univ Sem, BR-09606045 Sao Bernardo Do Campo, SP, Brazil
基金
巴西圣保罗研究基金会;
关键词
chitosan; thermoresponsive hydrogel; nitric oxide; S-nitrosothiols; biocompatibility; antimicrobial; Pseudomonas aeruginosa; Pluronic F127; S-NITROSOGLUTATHIONE; POLY(VINYL ALCOHOL); THERMOSENSITIVE HYDROGEL; BIOMEDICAL APPLICATIONS; PSEUDOMONAS-AERUGINOSA; POTENTIAL USES; CHITOSAN; DELIVERY; SYSTEMS; SKIN;
D O I
10.3390/polym10040452
中图分类号
O63 [高分子化学(高聚物)];
学科分类号
070305 ; 080501 ; 081704 ;
摘要
Nitric oxide (NO) is involved in physiological processes, including vasodilatation, wound healing and antibacterial activities. As NO is a free radical, designing drugs to generate therapeutic amounts of NO in controlled spatial and time manners is still a challenge. In this study, the NO donor S-nitrosoglutathione (GSNO) was incorporated into the thermoresponsive Pluronic F-127 (PL)-chitosan (CS) hydrogel, with an easy and economically feasible methodology. CS is a polysaccharide with known antimicrobial properties. Scanning electron microscopy, rheology and differential scanning calorimetry techniques were used for hydrogel characterization. The results demonstrated that the hydrogel has a smooth surface, thermoresponsive behavior and good mechanical stability. The kinetics of NO release and GSNO diffusion from GSNO-containing PL/CS hydrogel demonstrated a sustained NO/GSNO release, in concentrations suitable for biomedical applications. The GSNO-PL/CS hydrogel demonstrated a concentration-dependent toxicity to Vero cells, and antimicrobial activity to Pseudomonas aeruginosa (minimum inhibitory concentration and minimum bactericidal concentration values of 0.5 mu g.mL(-1) of hydrogel, which corresponds to 1 mmol.L-1 of GSNO). Interestingly, the concentration range in which the NO-releasing hydrogel demonstrated an antibacterial effect was not found to be toxic to the Vero mammalian cell. Thus, the GSNO-PL/CS hydrogel is a suitable biomaterial for topical NO delivery applications.
引用
收藏
页数:19
相关论文
共 96 条
[1]  
Adams R, 1990, CELL CULTURE BIOCH
[2]   Recent progress in biomedical applications of Pluronic (PF127): Pharmaceutical perspectives [J].
Akash, Muhammad Sajid Hamid ;
Rehman, Kanwal .
JOURNAL OF CONTROLLED RELEASE, 2015, 209 :120-138
[3]   In situ gelling systems based on Pluronic F127/Pluronic F68 formulations for ocular drug delivery [J].
Al Khateb, Kosai ;
Ozhmukhametova, Elvira K. ;
Mussin, Marat N. ;
Seilkhanov, Serzhan K. ;
Rakhypbekov, Tolebai K. ;
Lau, Wing Man ;
Khutoryanskiy, Vitaliy V. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2016, 502 (1-2) :70-79
[4]  
Ammerman Nicole C, 2008, Curr Protoc Microbiol, VAppendix 4, p4E, DOI 10.1002/9780471729259.mca04es11
[5]  
[Anonymous], 2009, Biological evaluation of medical devices - part 5:tests for in vitro cytotoxity, DOI DOI 10.2345/9781570203558.CH1
[6]  
[Anonymous], NITRIC OXIDE BIOL PA
[7]  
[Anonymous], NITRIC OXIDE DONORS
[8]  
[Anonymous], MOL PHARM
[9]   Nitric Oxide Signaling in Pseudomonas aeruginosa Biofilms Mediates Phosphodiesterase Activity, Decreased Cyclic Di-GMP Levels, and Enhanced Dispersal [J].
Barraud, Nicolas ;
Schleheck, David ;
Klebensberger, Janosch ;
Webb, Jeremy S. ;
Hassett, Daniel J. ;
Rice, Scott A. ;
Kjelleberg, Staffan .
JOURNAL OF BACTERIOLOGY, 2009, 191 (23) :7333-7342
[10]   Chitosan-based drug delivery systems [J].
Bernkop-Schnuerch, Andreas ;
Duennhaupt, Sarah .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2012, 81 (03) :463-469